LAUSR

Submit Manuscript | http://medcraveonline.com 66% in P group vs 63% in placebo group). This increase was not statistically significant (p=0.243 and p=0.45 respectively). Despite the absence of numerical significance, this augmentation mirrors the clinical improvement that P could induce in cases where the risk of abortion predominates. Differentiation in treatment (different chemical variants of P or unlike way of administration: per os, vaginally or rectal) did not affect P s effectiveness [2,4]. But it should be noticed the crucial different role of dydrogesterone; its administration resulted in 47% significant decrease in odds ratio for miscarriage and in 26% significant increase in live birth rates compared to women that were treated either by placebo or bed rest [5]. Dydrogesterone should be further prospectively evaluated in cases of symptomatic pregnant women menaced by the risk of preterm labor.